Abstract
Background Allosensitization in pediatric heart transplantation (HT) is a challenging problem, with ongoing uncertainty as to optimal management strategy. Patients with congenital heart disease (CHD) have the highest risk of allosensitization and may be at risk for inferior outcomes following HT due to an accumulation of risk factors.
Methods The United Network for Organ Sharing database was studied for all patients <18 years of age with CHD undergoing HT between April 2015 and December 2020. Patients were grouped into three categories of allosensitization status based on calculated panel reactive antibody (cPRA) obtained closest to the time of HT: nonsensitized (cPRA <10%), moderately sensitized (cPRA 10% - <80%), and highly sensitized (cPRA ≥80%). The primary outcome measures of interest were one-year patient and graft survival following HT. Multivariable analysis was used to control for differences in preoperative clinical characteristics among sensitization categories.
Results During the study period, 1086 patients with CHD underwent HT at a median of 3 years of age. Nonsensitized patients comprised 70% of the cohort; 22% were moderately sensitized and 9% were highly sensitized. Unadjusted 1-year mortality was 25% in the highly sensitized group compared to 8.7% in the nonsensitized group (P<0.001). After adjustment, highly sensitized patients were >3 times more likely to die within the first year than nonsensitized patients (HR 3.44, 95% CI 2.13 - 5.54, P<0.001). The relationship between cPRA and crossmatch result was also assessed using multivariable regression. A variety of crossmatches were performed, including cytotoxicity and flow cytometry modalities. Regardless of crossmatch result, highly sensitized patients had an increased risk of one-year mortality and graft failure compared to nonsensitized and moderately sensitized patients (HR 3.4, 95% CI 1.98 – 5.84, P<0.001 and HR 3.32, 95% CI 1.94 – 5.67, P<0.001 for one-year mortality and the composite of death or graft failure, respectively).
Conclusions Highly sensitized patients with CHD undergoing HT in the current era experience 25% 1-year mortality, which is significantly worse than less sensitized or nonsensitized patients. The magnitude of sensitization as reflected by cPRA, is highly predictive of adverse outcomes. These at-risk patients remain in need of more effective therapies for desensitization and management of the consequences of anti-HLA antibodies following HT.
What is New?
Allosensitization to HLA antigens is a common problem in pediatric heart transplantation, and outcomes remain suboptimal in allosensitized patients undergoing heart transplantation. Patients with CHD are at the highest risk of allosensitization.
In the current study, highly sensitized children with CHD undergoing heart transplantation in the current era experience 25% 1-year mortality following heart transplantation, which is significantly higher than in other groups undergoing transplantation.
Allosensitization status, regardless of crossmatch result, independently predicted mortality following heart transplantation in this cohort.
What are the Clinical Implications?
Highly sensitized patients with CHD are much more likely to die in the first year following heart transplantation than less- or nonsensitized patients. They also experience higher rates of rejection, which contributes to morbidity and late mortality.
Many efforts are made to minimize the likelihood of a positive crossmatch at the time of transplantation in order to optimize outcomes. However, the results of this study indicate that allosensitization status is the primary driver of outcomes when both allosensitization status and crossmatch result are taken into account. Therefore, continued development of new therapies for desensitization is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was not human subjects research (deidentified data) so local IRB review/approval not applicable.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request and after execution of a data use agreement. The first and senior authors of the manuscript (MJO, JBE) had full access to all of the data and the study and take responsibility for its integrity and the data analysis.
Non-standard Abbreviations and Acronyms
- HT
- heart transplantation
- CHD
- congenital heart disease
- cPRA
- calculated panel reactive antibody
- UNOS
- United Network for Organ Sharing
- OPTN
- Organ Procurement and Transplantation Network
- DSA
- Donor-specific antibody
